Further, similar therapeutic benefits of combination treatment were observed in mice bearing 4T1-hPDL1-OTUD4–OE tumors (Figure 6, R and S), where durvalumab monotherapy failed to suppress tumor growth compared with IgG control. The gene discussed is OTUD4; the disease is neoplasm.